Nutriband Inc
NTRB7.500USD
+0.110+1.49%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
83.06MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Nutriband Inc Unternehmen
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Unternehmensinformationen
BörsenkürzelNTRB
Name des UnternehmensNutriband Inc
IPO-datumJun 20, 2017
CEOMr. Gareth Sheridan
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeJun 20
Addresse121 S Orange Ave Ste 1500
StadtORLANDO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl32801-3241
Telefon14073776695
Websitehttps://nutriband.com/
BörsenkürzelNTRB
IPO-datumJun 20, 2017
CEOMr. Gareth Sheridan
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.76M
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.76M
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Sale of goods
667.43K
0.00%
Services
0.00
0.00%
Nach RegionUSD
Name
Umsatz
Anteil
United States
667.43K
100.00%
Non-United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Sale of goods
667.43K
0.00%
Services
0.00
0.00%
Aktionärsstatistik
Aktualisiert: Sun, Jul 20
Aktualisiert: Sun, Jul 20
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Botgros (Vitalie)
27.68%
TII Jet Services, LDA
16.21%
Sheridan (Gareth)
15.79%
Glinka (Serguei)
7.40%
Melnik (Serguei)
7.36%
Other
25.57%
Aktionäre
Aktionäre
Anteil
Botgros (Vitalie)
27.68%
TII Jet Services, LDA
16.21%
Sheridan (Gareth)
15.79%
Glinka (Serguei)
7.40%
Melnik (Serguei)
7.36%
Other
25.57%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
60.16%
Corporation
16.21%
Investment Advisor
2.09%
Investment Advisor/Hedge Fund
0.83%
Research Firm
0.12%
Other
20.59%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
44
8.86M
79.41%
+467.78K
2025Q1
43
8.13M
73.14%
+1.78M
2024Q4
40
8.04M
72.39%
+1.68M
2024Q3
40
8.08M
72.79%
+1.82M
2024Q2
38
5.19M
52.25%
+2.18M
2024Q1
34
4.36M
55.65%
+1.38M
2023Q4
30
4.30M
54.90%
+1.31M
2023Q3
29
2.96M
37.78%
-39.44K
2023Q2
28
2.95M
37.71%
-29.57K
2023Q1
28
2.96M
37.92%
-64.00
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Botgros (Vitalie)
3.09M
27.68%
+716.50K
+30.22%
Apr 25, 2025
TII Jet Services, LDA
1.81M
16.21%
+485.05K
+36.66%
Sep 01, 2024
Sheridan (Gareth)
1.76M
15.79%
-103.00
-0.01%
Apr 25, 2025
Glinka (Serguei)
825.00K
7.4%
--
--
Apr 25, 2025
Melnik (Serguei)
820.42K
7.36%
--
--
Apr 25, 2025
The Vanguard Group, Inc.
199.03K
1.78%
+74.44K
+59.75%
Mar 31, 2025
Goodman (Gerald)
86.33K
0.77%
--
--
Apr 25, 2025
Geode Capital Management, L.L.C.
63.55K
0.57%
+1.11K
+1.79%
Mar 31, 2025
Smith (Allan)
41.91K
0.38%
-6.99K
-14.29%
Apr 25, 2025
Patrick (Jeff)
36.61K
0.33%
--
--
Apr 25, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jul 29, 2022
Split
6>7
Datum
Art
Verhältnis
Jul 29, 2022
Split
6>7
